Close Menu

NEW YORK (GenomeWeb) — Highmark Health announced today that it will study the clinical and economic impact of Biocept's Target Selector liquid biopsy in patients with non-small cell lung cancer.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.